

订购热线: 4008-898-798

Anti-ARHGAP45 antibody

Cat. No. ml264144

Package 25 μl/100 μl/200 μl

Storage -20°C, pH7.4 PBS, 0.05% NaN3, 40% Glycerol

Product overview

Description Anti-ARHGAP45 rabbit polyclonal antibody

Applications ELISA, IHC

Immunogen Synthetic peptide of human ARHGAP45

Reactivity Human

Content 0.54 mg/ml

Host species Rabbit

Ig classImmunogen-specific rabbit IgGPurificationAntigen affinity purification

Target information

Symbol ARHGAP45

Full name Rho GTPase activating protein 45

Synonyms HA-1; HMHA1; HLA-HA1

Swissprot Q92619

Target Background

Contains a GTPase activator for the Rho-type GTPases (RhoGAP) domain that would be able to negatively regulate the actin cytoskeleton as well as cell spreading. However, also contains N-terminally a BAR-domin which is able to play an autoinhibitory effect on this RhoGAP activity. Precursor of the histocompatibility antigen HA-1. More generally, minor histocompatibility antigens (mHags) refer to immunogenic peptide which, when complexed with MHC, can generate an immune response after recognition by specific T-cells. The peptides are derived from polymorphic intracellular proteins, which are cleaved by normal pathways of antigen processing. The binding of these peptides to MHC class I or class II molecules and its expression on the cell surface can stimulate T-cell responses and thereby trigger graft rejection or graft-versus-host disease (GVHD) after hematopoietic stem cell transplantation from HLA-identical sibling donor. GVHD is a frequent complication after bone marrow transplantation (BMT), due to mismatch of minor histocompatibility antigen in HLA-matched sibling marrow transplants. Specifically, mismatching for mHag HA-1 which is recognized as immunodominant, is shown to be associated with the development of severe GVHD after HLA-identical BMT. HA-1 is presented to the cell surface by MHC class I HLA-A*0201, but also by other HLA-A alleles. This complex specifically elicits donor-cytotoxic T-lymphocyte (CTL) reactivity against hematologic malignancies after treatment by HLA-identical allogenic BMT. It induces cell recognition and lysis by CTL.




订购热线: 4008-898-798


Applications

Immunohistochemistry

Predicted cell location: Cytoplasm Positive control: Human breast cancer

Recommended dilution: 10-50





The image on the left is immunohistochemistry of paraffin-embedded Human breast cancer tissue using ml264144(ARHGAP45 Antibody) at dilution 1/20, on the right is treated with synthetic peptide. (Original magnification: ×200)

ELISA

Recommended dilution: 5000-10000

联系电话: 4008-898-798, 021-61725725

联系QQ: 2881505695, 2881505696

邮箱: mlbio_cn@yeah.net 网址: www.mlbio.cn